Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo’s Oxymorphone Solid Tablet Could Be Unscathed By Palladone Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

Purdue’s withdrawal of its opiate Palladone may not impact Endo’s pending oxymorphone product because of formulation differences, the company says. Endo hopes to avoid marketing restrictions for oxymorphone based on a broad clinical development program.

You may also be interested in...



Endo Submits "Complete Response" For Oxymorphone ER

Filing includes data from two additional clinical trials in opioid-naive and opioid-experienced patients, company says.

Endo Submits "Complete Response" For Oxymorphone ER

Filing includes data from two additional clinical trials in opioid-naive and opioid-experienced patients, company says.

FDA Requests Expanded Alcohol Warnings For Extended-Release Morphine Kadian

Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel